AU2013266421B2 - Murine anti-NY-ESO-1 T cell receptors - Google Patents

Murine anti-NY-ESO-1 T cell receptors Download PDF

Info

Publication number
AU2013266421B2
AU2013266421B2 AU2013266421A AU2013266421A AU2013266421B2 AU 2013266421 B2 AU2013266421 B2 AU 2013266421B2 AU 2013266421 A AU2013266421 A AU 2013266421A AU 2013266421 A AU2013266421 A AU 2013266421A AU 2013266421 B2 AU2013266421 B2 AU 2013266421B2
Authority
AU
Australia
Prior art keywords
tcr
seq
eso
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013266421A
Other languages
English (en)
Other versions
AU2013266421A1 (en
Inventor
Richard A. Morgan
Maria R. Parkhurst
Shannon Faith Rosati
Steven A. Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2013266421A1 publication Critical patent/AU2013266421A1/en
Application granted granted Critical
Publication of AU2013266421B2 publication Critical patent/AU2013266421B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013266421A 2012-05-22 2013-05-22 Murine anti-NY-ESO-1 T cell receptors Active AU2013266421B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650020P 2012-05-22 2012-05-22
US61/650,020 2012-05-22
PCT/US2013/042162 WO2013177247A1 (en) 2012-05-22 2013-05-22 Murine anti-ny-eso-1 t cell receptors

Publications (2)

Publication Number Publication Date
AU2013266421A1 AU2013266421A1 (en) 2014-12-04
AU2013266421B2 true AU2013266421B2 (en) 2017-06-01

Family

ID=48539439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013266421A Active AU2013266421B2 (en) 2012-05-22 2013-05-22 Murine anti-NY-ESO-1 T cell receptors

Country Status (10)

Country Link
US (3) US9487573B2 (enExample)
EP (3) EP3828197B1 (enExample)
JP (2) JP6378172B2 (enExample)
CN (2) CN104507963B (enExample)
AU (1) AU2013266421B2 (enExample)
CA (1) CA2874486C (enExample)
ES (3) ES2835200T3 (enExample)
IL (1) IL235720A0 (enExample)
PT (2) PT3527584T (enExample)
WO (1) WO2013177247A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2835200T3 (es) * 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
ES2949648T3 (es) 2012-12-20 2023-10-02 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
CA2934729C (en) * 2014-01-29 2021-08-17 University Health Network Methods and compositions for producing a cell expressing a t cell receptor
CN107206024B (zh) 2014-10-31 2021-12-03 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
CN107922471A (zh) * 2015-06-24 2018-04-17 优瑞科生物技术公司 靶向ny‑eso‑1肽/mhc复合物的构建体及其用途
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017076308A1 (zh) * 2015-11-04 2017-05-11 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的tcr
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
AU2018207172B2 (en) 2017-01-13 2023-10-12 Mink Therapeutics, Inc. T cell receptors that bind to NY-ESO-1 and methods of use thereof
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
EP3579877A4 (en) * 2017-02-09 2020-12-09 The Regents of The University of California CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
US10386882B2 (en) * 2017-04-14 2019-08-20 Allegro Microsystems, Llc Control circuit
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
AU2018326805B2 (en) 2017-09-01 2023-11-30 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
IL273698B2 (en) 2017-10-05 2025-07-01 Us Health Methods for selectively expanding cells expressing a tcr with a murine constant region
KR20200063215A (ko) 2017-10-06 2020-06-04 오슬로 유니버시테시케후스 에이치에프 키메라 항원 수용체
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
EP3749770B9 (en) 2018-02-09 2025-12-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Tethered interleukin-15 and interleukin-21
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US11267864B2 (en) * 2018-02-26 2022-03-08 Medigene Immunotherapies Gmbh Nyeso tcr
US12415845B2 (en) 2018-04-24 2025-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
CN110856751B (zh) * 2018-08-24 2024-12-03 杭州康万达医药科技有限公司 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用
EP3847265A4 (en) * 2018-09-05 2023-02-15 The Regents of University of California COMPOSITION OF NY-ESO-1-SPECIFIC T-CELL RECEPTORS RESTRICTED TO MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES
EA202191107A1 (ru) * 2018-10-23 2021-09-17 Ридженерон Фармасьютикалз, Инк. T-клеточные рецепторы ny-eso-1 и способы их применения
CA3131138A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
CA3191211A1 (en) 2020-09-08 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
CN112375136B (zh) * 2020-11-03 2022-06-07 中国科学院微生物研究所 Ny-eso-1特异性t细胞受体筛选及其抗肿瘤用途
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CA3241588A1 (en) 2021-12-31 2023-07-06 Sri Krishna T cell therapy with vaccination as a combination immunotherapy against cancer
WO2025077869A1 (en) * 2023-10-13 2025-04-17 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ny-eso-1 antibodies and uses thereof
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042570A2 (en) * 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO1999018129A1 (en) * 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
CN1269412A (zh) * 2000-03-17 2000-10-11 国家人类基因组南方研究中心 一种新的人t细胞受体相关蛋白及其编码序列
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2003020763A2 (en) 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
EP2016102B1 (en) 2006-05-03 2012-03-21 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Chimeric t cell receptors and related materials and methods of use
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
MX2009009926A (es) * 2007-03-13 2010-03-15 Univ Zuerich Anticuerpo tumor-especifico humano monoclonal.
EP3213765B1 (en) * 2010-09-20 2019-08-28 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
ES2835200T3 (es) * 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042570A2 (en) * 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Robbins P.F. et al. "Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1" Journal of Clinical Oncology (2011) 29(7): 917-924 *
Wargo J.A. et al. "Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression" Cancer Immunol Immunother (2009) 58: 383-394 *

Also Published As

Publication number Publication date
EP3527584B8 (en) 2020-12-16
ES2835200T3 (es) 2021-06-22
CA2874486C (en) 2021-08-24
HK1251874A1 (zh) 2019-04-26
EP2852613A1 (en) 2015-04-01
US20170029483A1 (en) 2017-02-02
US20180371050A1 (en) 2018-12-27
CN104507963A (zh) 2015-04-08
EP3527584A1 (en) 2019-08-21
EP3828197A1 (en) 2021-06-02
WO2013177247A1 (en) 2013-11-28
JP2015525208A (ja) 2015-09-03
CA2874486A1 (en) 2013-11-28
EP3828197B1 (en) 2024-10-02
US10407485B2 (en) 2019-09-10
US10087230B2 (en) 2018-10-02
AU2013266421A1 (en) 2014-12-04
US9487573B2 (en) 2016-11-08
EP3527584B1 (en) 2020-10-14
JP6378172B2 (ja) 2018-08-22
CN104507963B (zh) 2017-12-15
CN107881183B (zh) 2021-04-02
EP2852613B1 (en) 2019-01-23
IL235720A0 (en) 2015-01-29
ES2998514T3 (en) 2025-02-20
PT3527584T (pt) 2021-01-04
US20150141347A1 (en) 2015-05-21
ES2718474T3 (es) 2019-07-02
CN107881183A (zh) 2018-04-06
PT2852613T (pt) 2019-05-20
JP2018196384A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
US10407485B2 (en) Murine anti-NY-ESO-1 T cell receptors
US12441778B2 (en) T cell receptors recognizing HLA-A1-restricted MAGE-A3
EP4159753A1 (en) T cell receptors recognizing mhc class ii-restricted mage-a3
WO2012054825A1 (en) Anti-mage-a3 t cell receptors and related materials and methods of use
HK1262936A1 (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
HK1262936B (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
HK1251874B (zh) 鼠抗-ny-eso-1 t细胞受体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)